Granted Patent
B2
US 12,282,028 · App. 18/420,177 · Granted Apr 22, 2025
Atomic description of immune complex that causes heparin-induced thrombocytopenia
Inventors:
Mark I. Greene (Penn Valley, PA); Douglas B. Cines (Wynnewood, PA); Zheng Cai (Wynnewood, PA); Zhiqiang Zhu (Philadelphia, PA)
G01N33/6863A61K38/195A61K39/3955C07K14/522C07K16/24G01N33/86A61K2039/505G01N2333/522G01N2400/40G01N2800/222G01N2800/50G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a mutant protein which has the same amino acid sequence of a wild type PF4 monomer except that (i) at least one amino acid of the wild type PF4 monomer has been deleted, (ii) at least one amino acid of the wild type PF4 monomer has been replaced by another amino acid, or (iii) a combination of such changes has been made. The present invention also provides methods of treating or reducing the likelihood of HIT, treating angiogenesis, treating abnormal cell growth, or affecting coagulation pathologies that lead to thrombus formation, by administering such mutant proteins to a patient.
Claims (5)
1. A mutant platelet factor 4 (PF4) monomer comprising amino acids 9 to 70 of SEQ ID NO: 11 and having a Q9S substitution relative to the amino acid sequence of SEQ ID NO: 11.
2. The mutant PF4 monomer of claim 1 , further comprising a L11V substitution relative to the amino acid sequence of SEQ ID NO: 11.
3. The mutant PF4 monomer of claim 1 , further comprising a K50E substitution relative to SEQ ID NO: 11.
4. The mutant PF4 monomer of claim 1 , further comprising a L55R substitution relative to the amino acid sequence of SEQ ID NO: 11.
5. The mutant PF4 monomer of claim 1 , further comprising a L11V substitution and a L55R substitution relative to the amino acid sequence of SEQ ID NO: 11.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 27, 2024
From: GREENE, MARK I.; CINES, DOUGLAS B.; CAI, ZHENG; ZHU, ZHIQIANG
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 066571/0641 →
Continuity (6)
Continuation
15524511
Provisional Application
62221485
· Sep 21, 2015
Provisional Application
62076213
· Nov 6, 2014
References Cited (89)
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5693761A
· Queen et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5739103A
· Rollins et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 5939598A
· Kucherlapati et al.
· 1999
[cited by applicant]
CA 2204731A1
· 1996
[cited by applicant]
Presta, “Antibody engineering,” Current Opinion in Structural Biology, 1992, vol. 2, No. 4, pp. 593-596.
[cited by applicant]
Rauova et al., “Monocytebound PF4 In The Pathogenesis Of Heparin-Induced Thrombocytopenia”, Blood, 2010, vol. 116, pp. 5021-5031.
[cited by applicant]
Rauova et al., “Role Of Platelet Surface PF4 Antigenic Complexes In Heparin-Induced Thrombocytopenia Pathogenesis: Diagnostic And Therapeutic Implications”, Blood, 2006, vol. 107, pp. 2346-2353.
[cited by applicant]
Rauova et al., “Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia”, Blood, 2005, vol. 105, pp. 131-138.
[cited by applicant]
Reilly et al., “Heparin-Induced Thrombocytopenia/Thrombosis In A Transgenic Mouse Model Requires Human Platelet Factor 4 And Platelet Activation Through FcgammaRIIA”, Blood, 2001, vol. 98, pp. 2442-2447.
[cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy”, Nature, 1988, vol. 332, pp. 323-327.
[cited by applicant]
Rota et al., “Fondaparinux-Related Thrombocytopenia In A Previous Low-Molecular-Weight Heparin (LMWH)-Induced Heparin-Induced Thrombocytopenia (HIT)”, Thromb Haemost, 2008, vol. 99, pp. 779-781.
[cited by applicant]
Sachais et al., “Dynamic antibody-binding properties in the pathogenesis of HIT”, Blood, 2012, vol. 120, pp. 1137-1142.
[cited by applicant]
Sachais et al., “Rational Design And Characterization Of Platelet Factor 4 Antagonists For The Study Of Heparin-Induced Thrombocytopenia”, Blood, 2012, vol. 119, pp. 5955-5962.
[cited by applicant]
Schroder et al., Superresolution Biomolecular Crystallography With Low-Resolution Data, Nature, 2010, vol. 464, pp. 1218-1222.
[cited by applicant]
Strog et al., “Toward The Structural Genomics Of Complexes: Crystal Structure Of A PE/PPE Protein Complex From
[cited by applicant]
Stuckey et al., “A Model Of The Platelet Factor 4 Complex With Heparin”, Proteins, 1992, vol. 14, pp. 277-287.
[cited by applicant]
Turpie et al., “Postoperative Fondaparinux Versus Postoperative Enoxaparin For Prevention Of Venous Thromboembolism After Elective Hip-Replacement Surgery: A Randomised Double-Blind Trial”, Lancet, 2002, vol. 359, pp. 1…
[cited by applicant]
UnitProt Accession No. P02776, accessed at URL www.uniprot.org/uniprot/P02776, Apr. 10, 2021 (Year: 2021).
[cited by applicant]
Vagin et al., “Molecular replacement with MOLREP”, Acta Crystallogr D Biol Crystallogr, 2010, vol. 66, pp. 22-25.
[cited by applicant]
Visentin et al., “Heparin Is Not Required For Detection Of Antibodies Associated With Heparin-Induced Thrombocytopenia/Thrombosis”, J Lab Clin Med, 2001, vol. 138, pp. 22-31.
[cited by applicant]
Warkentin et al., “Anti-Platelet Factor 4/Heparin Antibodies In Orthopedic Surgery Patients Receiving Antithrombotic Prophylaxis With Fondaparinux Or Enoxaparina”, Blood, 2005, vol. 106, pp. 3791-3796.
[cited by applicant]
Warkentin et al., “Can Heparin-Induced Thrombocytopenia Be Associated With Fondaparinux Use? Reply To A Rebuttal”, J Thromb Haemost, 2008, vol. 6, pp. 1243-1246.
[cited by applicant]
Warkentin et al., “Heparininduced Thrombocytopenia Associated With Fondaparinux”, N Engl J Med, 2007, vol. 356, pp. 2653-2655.
[cited by applicant]
Winn et al., “Overview Of The CCP4 Suite And Current Developments”, Acta Crystallogr D Biol Crystallogr, 2011, vol. 67, pp. 235-242.
[cited by applicant]
Xiao et al., “Immune Complexes Formed Following The Binding Of Anti-Platelet Factor 4 (CXCL4)”, Blood, 2008, vol. 112, pp. 1091-1100.
[cited by applicant]
Xiao et al., “Supplemental Materials and Methods”, Blood, 2008, vol. 112, pp. S1-S3.
[cited by applicant]
Zhang et al., “Crystal Structure Of Recombinant Human Platelet Factor4”, Biochemistry, 1994, vol. 33, pp. 8361-8366.
[cited by applicant]
Ziporen et al., “Defining An Antigenic Epitope On Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia”, Blood, 1998, vol. 92, pp. 3250-3259.
[cited by applicant]
U.S. Appl. No. 17/929,524, filed Sep. 2, 2022.
[cited by applicant]
U.S. Appl. No. 16/446,902, filed Jun. 20, 2019.
[cited by applicant]
U.S. Appl. No. 15/524,511, filed May 4, 2017.
[cited by applicant]
Afonine et al., “Towards Automated Crystallographic Structure Refinement With Phenix.Refine”, Acta Crystallogr D Biol Crystallogr, 2012, vol. 68, pp. 352-367.
[cited by applicant]
Amiral et al., “Antibodies To Macromolecular Platelet Factor 4- Heparin Complexes In Heparin-Induced Thrombocytopenia: A Study Of 44 Cases”, Thromb Haemost, 1995, vol. 73, pp. 21-28.
[cited by applicant]
Arepally et al., “Characterization Of A Murine Monoclonal Antibody That Mimics Heparin-Induced Thrombocytopenia Antibodies”, Blood, 2000, vol. 95, pp. 1533-1540.
[cited by applicant]
Baker et al., “Electrostatics Of Nanosystems: Application To Microtubules And The Ribosome”, Proc Natl Acad Sci USA, 2001, vol. 98, pp. 10037-10041.
[cited by applicant]
Bauer et al., “Fondaparinux Compared With Enoxaparin For The Prevention Of Venous Thromboembolism After Elective Major Knee Surgery”, N Engl J Med, 2001, vol. 345, pp. 1305-1310.
[cited by applicant]
Bhatt et al., “Fondaparinux-Associated Heparin-Induced Thrombocytopenia”, Eur J Haematol, 2013, vol. 91, pp. 437-441.
[cited by applicant]
Block et al., “Characterization Of Bonds Formed Between Platelet Factor 4 And Negatively Charged Drugs Using Single Molecule Force Spectroscopy”, Soft Matter, 2014, vol. 10, pp. 2775-2784.
[cited by applicant]
Brandt et al., “Characterisation Of The Conformational Changes In Platelet Factor 4 Induced By Polyanions: Towards In Vitro Prediction Of Antigenicity”, Thromb Haemost, 2014, vol. 112, pp. 53-64.
[cited by applicant]
Burch et al., “Fondaparinux-Associated Heparininduced Thrombocytopenia”, Proc Bayl Univ Med Cent, 2012, vol. 25, pp. 13-15.
[cited by applicant]
Chen et al., “Molprobity: All-Atom Structure Validation For Macromolecular Crystallography”, Acta Crystallogr D. Biol Crystallogr, 2010, vol. 66, pp. 12-21.
[cited by applicant]
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol., 1987, vol. 196, pp. 901-917.
[cited by applicant]
Clackson et al, “Making antibody fragments using phage display libraries”, Nature, 1991, vol. 352, pp. 624-628.
[cited by applicant]
Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, pp. 77-96.
[cited by applicant]
Cowan et al., “Binding Of Heparin To Human Platelet Factor 4”, Biochem J., 1986, vol. 234, pp. 485-488.
[cited by applicant]
Cuker et al., “How | Treat Heparin-Induced Thrombocytopenia”, Blood, 2012, vol. 119, pp. 2209-2218.
[cited by applicant]
Cuker et al., “Novel Diagnostic Assays For Heparin-Induced Thrombocytopenia”, Blood, 2013, vol. 121, pp. 3727-3732.
[cited by applicant]
Eisman et al., “Structural And Functional Comparison Of The Genes For Human Platelet Factor 4 And PF4,” Blood, 1990, vol. 76, No. 2, pp. 336-344.
[cited by applicant]
Eke et al., “Heparin-Induced Thrombocytopenia”, Medscape, Ed. Emmanuel Besa, 2014, pp. 1-18, Available at: Ernedicine.Medscape.Com/Article/135784 6-Overview.
[cited by applicant]
Emsley et al., “Features And Development Of Coot”, Acta Crystallogr D Biol Crystallogr, 2010, vol. 66, pp. 486-501.
[cited by applicant]
Falati et al., “Real-Time In Vivo Imaging Of Platelets, Tissue Factor And Fibrin During Arterial Thrombus Formation In The Mouse”, Nat Med., 2002, vol. 8, pp. 1175-1181.
[cited by applicant]
Funatsu et al., “Stimulation And Inhibition Of Angiogenesis In Diabetic Retinopathy”, Jpn J Ophthalmol. 2001, vol. 45, No. 6, pp. 577-584.
[cited by applicant]
Greinacher et al., “Characterization Of The Structural Requirements For A Carbohydrate Based Anticoagulant With A Reduced Risk Of Inducing The Immunological Type Of Heparin-Associated Thrombocytopenia”, Thromb Haemost, …
[cited by applicant]
Greinacher et al., “Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies”, Arterioscler Thromb Vase Biol., 2006, vol. 26, pp. 2386-2393.
[cited by applicant]
Gupta et al., “A Potent Inhibitor Of Endothelial Cell Proliferation Is Generated By Proteolytic Cleavage Of The Chemokine Platelet Factor 4,” PNAS 1995, vol. 92, pp. 7799-7803.
[cited by applicant]
Jones et al., “Replacing the complementarity determining regions in a human antibody with those from a mouse”, Nature, 1986, vol. 321, pp. 522-525.
[cited by applicant]
Kang et al., “Fondaparinux For The Treatment Of Suspected Heparin-Induced Thrombocytopenia: A Propensity Score-Matched Study”, Blood, 2015, vol. 125, pp. 924-929.
[cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”, Nature, 1975, vol. 256, No. 5517, pp. 495-497.
[cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes”, Immunology Today, 1983, vol. 4, No. 3, pp. 72-79.
[cited by applicant]
Kreimann et al., “Binding Of Anti-Platelet Factor 4/Heparin Antibodies Depends On The Thermodynamics Of Conformational Changes In Platelet Factor 4”, Blood, 2014, vol. 124, pp. 2442-2449.
[cited by applicant]
Laskowski et al., “PROCHECK: a program to check the stereochemical quality of protein structures”, J. Appl Cryst, 1993, vol. 26, pp. 283-291.
[cited by applicant]
Lecomte et al., “New Insights Into the Negative Regulation of Hematopoiesis by Chemokine Platelet Factor 4 and Related Peptides,” Blood, 1998, vol. 91, pp. 2772-2780.
[cited by applicant]
Lee et al., “Heparin-Induced Thrombocytopenia”, Hematology Am Soc Hematol Educ Program, 2013, vol. 2013, pp. 668-674.
[cited by applicant]
Lewis et al., “Argatroban Anticoagulation In Patients With Heparin-Induced Thrombocytopenia”, Arch Intern Med. 2003, vol. 163, pp. 1849-1856.
[cited by applicant]
Li et al., “Defining A Second Epitope For Heparin-Induced Thrombocytopenia/Thrombosis Antibodies Using KKO, A Murine Hitlike Monoclonal Antibody”, Blood, 2002, vol. 99, pp. 1230-1236.
[cited by applicant]
Linkins et al., “Treatment And Prevention Of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy And Prevention Of Thrombosis, 9th Ed: American College Of Chest Physicians Evidence-Based Clinical Practice Guideline…
[cited by applicant]
Lippi et al., “Recombinant Platelet Factor 4: A Therapeutic, Antineoplastic Chimera?”, Semin Thromb Hemost., 2010, vol. 36, No. 5, pp. 558-569. Doi: 10.1055/S-0030-1255450. Epub Jul. 14, 2010.
[cited by applicant]
Liu et al., “Identification Of Critical Amino Acids In Human Platelet Factor 4 (PF4) Required For Its Modulatory Effects On CD4+CD 25+ Regulatory T Cells,” Blood, 2004, vol. 104, Issue. 11, pp. 3.
[cited by applicant]
Lu et al., “A New Method For Coarse-Grained Elastic Normal-Mode Analysis”, J Chem Theory Compu, 2006, vol. 2, pp. 464-471.
[cited by applicant]
Maione et al., “Inhibition Of Angiogenesis By Recombinant Human Platelet Factor-4 And Related Peptides”, Science, Jan. 1990, vol. 247, No. 4938, pp. 77-79, DOI: 10.1126/science.1688470.
[cited by applicant]
Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage”, J. Mol. Biol., 1991, vol. 222, pp. 581-597.
[cited by applicant]
Mayo et al., “Human Platelet Factor 4 Monomerdimertetramer Equilibria Investigated By 1H NMR Spectroscopy”, Biochemistry, 1989, vol. 28, pp. 9469-9478.
[cited by applicant]
Mayo et al., “Heparin Binding To Platelet Factor-4. An NMR And Sitedirected Mutagenesis Study: Arginine Residues Are Crucial For Binding”, Biochem J, 1995, vol. 312, pp. 357-365.
[cited by applicant]
Mayo et al., “NMR Solution Structure Of The 32-Kda Platelet Factor 4 ELR-Motif N-Terminal Chimera: A Symmetric Tetramer”, Biochemistry, 1995, vol. 34, pp. 11399-11409.
[cited by applicant]
McCoy et al., “Phaser Crystallographic Software”, J Appl Crystallogr, 2007, vol. 40, pp. 658-674.
[cited by applicant]
Murshudov et al., “Refinement of macromolecular structures by the maximum-likelihood method”, Acta Crystallogr D Biol Crystallogr, 1997, vol. 53, pp. 240-255.
[cited by applicant]
Murshudov et al., “REFMAC5 for the refinement of macromolecular crystal structures”, Acta Crystallogr D Biol Crystallogr, 2011, vol. 67, pp. 355-367.
[cited by applicant]
Nesmelova et al., “CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations”, J Biol Chem, 2008, vol. 283, pp. 24155-24166.
[cited by applicant]
Nguyen et al., “Quantitative Description Of Thermodynamic And Kinetic Properties Of The Platelet Factor 4/Heparin Bonds”, Nanoscale, 2015, vol. 7, pp. 10130-10139.
[cited by applicant]
Otwinowski et al., “Processing Of X-Ray Diffraction Data Collected In Oscillation Mode”, Methods In Enzymology, 1997, vol. 276, pp. 307-326.
[cited by applicant]
Phillips et al., “Considerations In Using Anticoagulant Therapy In Special Patient Populations”, Am J Health Syst Pharm, 2008, vol. 65, pp. S13-S21.
[cited by applicant]